SCHEMBL7119164

SCHEMBL7119164

Nc1cc(Cl)cc(Nc2nc3ccc(Cl)cc3s2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.60
RAB9A P51151 5/20 0.60
SMN1; SMN2 Q16637 5/20 0.60
MAPT P10636 3/20 0.60
MEN1 O00255 3/20 0.60
KMT2A Q03164 3/20 0.60
ALDH1A1 P00352 2/20 0.60
KDM4E B2RXH2 2/20 0.60
LMNA P02545 1/20 0.60
GAA P10253 1/20 0.60
ALOX12 P18054 1/20 0.60
HTT P42858 1/20 0.60
CASP3 P42574 6/20 0.50
SENP8 Q96LD8 6/20 0.50
SENP7 Q9BQF6 6/20 0.50
SENP6 Q9GZR1 6/20 0.50
DYRK1A Q13627 1/20 0.50
FSCN1 Q16658 1/20 0.50
APP P05067 1/20 0.47
CLK1 P49759 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1176219 0.77 NPC1 (0.59) NPC1RAB9ASMN1; SMN2MAPTMEN1
SCHEMBL2116067 0.76 MEN1 (1.00) NPC1RAB9ASMN1; SMN2MAPTMEN1
SCHEMBL5025802 0.75 NPC1 (0.68) NPC1RAB9ASMN1; SMN2MAPTMEN1
SCHEMBL7128046 0.74 CASP3 (0.47) NPC1RAB9ASMN1; SMN2MAPTMEN1
SCHEMBL1180003 0.73 DYRK1A (0.58) NPC1RAB9ASMN1; SMN2MAPTMEN1
SCHEMBL22468024 0.72 DYRK1A (0.65) NPC1RAB9ASMN1; SMN2MAPTMEN1
SCHEMBL12393158 0.72 MEN1 (0.70) NPC1RAB9ASMN1; SMN2MAPTMEN1
SCHEMBL12297548 0.72 SMN1; SMN2 (0.59) NPC1RAB9ASMN1; SMN2MAPTMEN1
SCHEMBL14006520 0.71 SMN1; SMN2 (0.68) NPC1RAB9ASMN1; SMN2MAPTMEN1
SCHEMBL15207606 0.70 SMN1; SMN2 (0.61) NPC1RAB9ASMN1; SMN2MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030176454-A1 N-coating heterocyclic compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-09-18 US disclosed
WO-2001087845-A2 N-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS 5-HT ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176454-A1 N-coating heterocyclic compounds H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 NPC1 310/4885RAB9A 1556/4885SMN1; SMN2 1496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.